Company profile: Orna Therapeutics
1.1 - Company Overview
Company description
- Provider of engineered circular RNA therapeutics and tools: isCAR therapy using oRNA and proprietary LNPs to modify immune cells for tumor control without lymphodepletion; oRNA-based dystrophin replacement via non-viral delivery to liver and muscle; next-generation vaccines with Merck using oRNA/LNP; and FoRCE for high-throughput oRNA sequence evaluation.
Products and services
- IsCAR™ therapy: Combines oRNA™ with proprietary LNPs to reprogram patient immune cells for tumor control without lymphodepletion, delivering circular RNA payloads (proprietary LNP-enabled)
- Vaccine development: Leverages the oRNA™ platform and LNP delivery to architect next-generation vaccine candidates with Merck, advancing circular RNA constructs for immunization (LNP-based)
- Dystrophin replacement therapy: Utilizes oRNA™ to deliver full-length dystrophin protein-coding RNA into human cells, targeting liver and muscle tissues as intended sites (non-viral)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Orna Therapeutics
Iveric Bio
HQ: United States
Website
- Description: Provider of science-driven biopharmaceutical research and development focused on novel treatment options for retinal diseases with significant unmet medical needs, including age-related macular degeneration, developing therapeutic product candidates for age-related retinal diseases and gene therapy product candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iveric Bio company profile →
Actogenix
HQ: Belgium
Website
- Description: Provider of biopharmaceutical development and commercialization of a new generation of biological drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Actogenix company profile →
Sangamo Therapeutics
HQ: United States
Website
- Description: Provider of engineered DNA-binding protein-based therapeutics, conducting clinical trials of gene and cell therapy candidates including: giroctocogene fitelparvovec for hemophilia A; ST-920 for Fabry disease; TX200 for patients undergoing a kidney transplant; SB-525/giroctocogene fitelparvovec (Phase 1/2); and BIVV003 ex vivo cell therapy for severe sickle cell disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sangamo Therapeutics company profile →
Advanced Cell Diagnostics
HQ: United States
Website
- Description: Provider of molecular pathology cell- and tissue-based diagnostic tests for personalized medicine, including RNAscope for single-molecule, high-specificity RNA detection in intact cells; BaseScope for detecting exon junctions and splice variants in FFPE tissue with morphological context; and miRNAscope for cell-type specific detection of miRNAs, siRNAs, and other small RNAs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advanced Cell Diagnostics company profile →
Camp4 Therapeutics
HQ: United States
Website
- Description: Provider of RNA-based therapeutics and platform technologies to restore healthy gene expression, including the RAP Platform to map regRNAs and select optimal chemistry, RNA Amplifiers to increase protein expression, programmable antisense oligonucleotide therapeutics targeting regRNA, and CMP-CPS-001 to amplify CPS1 mRNA for potential treatment of urea cycle disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Camp4 Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Orna Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Orna Therapeutics
2.2 - Growth funds investing in similar companies to Orna Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Orna Therapeutics
4.2 - Public trading comparable groups for Orna Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →